FROM THE EDITOR
For months the generic-drug tariff has been described as a schedule: zero percent until mid-2028, then 100 percent, then 200. That schedule came from a July 21 presidential statement. A statement is not a proclamation and it is not an annex. It is not part of the legal instrument that imposes the tariff, so it is not a source of rates you can write into a contract.
The operative document is Proclamation 11020, signed April 2, 2026 under Section 232 of the Trade Expansion Act of 1962. It imposes tariffs on patented pharmaceuticals, their active ingredients and key starting materials. Generics and biosimilars are outside it “at this time.” The staged generic schedule does not appear in the proclamation or its annexes.
That changes who needs to read it. This is a branded-company and licensee problem first, and a generic-company watch item second. This issue lays out what the text does and what your contracts need to say about it.
John LaRocca
WHAT THE PROCLAMATION DOES
The baseline. 100 percent ad valorem on patented pharmaceuticals and associated active ingredients listed in Annex I.
What “patented” means. As the Federal Register publication of the proclamation is summarized, a product is covered only if it has a valid, unexpired US patent and is listed in FDA’s Orange Book or Purple Book. The operative product scope is set by Annex I. Off-patent products, and products not so listed, fall outside the tariff.
Country rates. 15 percent for the European Union, Japan, Korea, Switzerland and Liechtenstein, unless a lower rate applies. 10 percent for the United Kingdom, falling to zero as required by a US-UK pharmaceutical pricing agreement, with a Federal Register notice if it reaches zero. The US-UK agreement was finalized on April 2, 2026, the day the proclamation was signed, so the UK rate is on a path to zero.
Company rates. Companies with a Commerce-approved onshoring plan, or expected to have one soon, pay 20 percent, rising to 100 percent on April 2, 2030. Companies with an onshoring plan and a most-favored-nation pricing agreement with HHS pay zero until January 20, 2029. The proclamation ratifies company-specific agreements listed in Annex II and lets the Commerce Secretary enter similar ones.
Zero-rate categories. Orphan-only drugs, nuclear medicines, plasma-derived therapies, fertility treatments, cell and gene therapies, antibody-drug conjugates, chemical, biological, radiological and nuclear countermeasures, animal health products, and other specialty products Commerce identifies. The condition: the product comes from a jurisdiction with a current or forthcoming trade and security framework agreement, or meets an “urgent United States health need.”
US-sourced API. Products made with US-sourced active pharmaceutical ingredient are exempt. A finished drug made abroad from US-origin API is not subject to the additional duty. For sourcing and supply agreements this is a lever: where the API can come from a US source, the tariff exposure on the finished product can fall away.
Effective dates. July 31, 2026 for companies in Annex III. September 29, 2026 for everyone else.
Generics. Excluded, with their ingredients and biosimilars, “at this time.” Commerce must report to the President within a year on whether circumstances warrant action on generics. That is the tail risk for generic makers. It is a report requirement, not a rate.
Stacking and administration. If the ordinary duty is below the Section 232 rate, the two together equal the Section 232 rate; if the ordinary duty is higher, only the ordinary duty applies. Where more than one rate applies, the lowest governs. Drawback is available. Foreign trade zone admissions generally must be privileged foreign status.
THE SEPTEMBER 23 NOTICE: WHAT IT ADDED
Commerce’s Bureau of Industry and Security published implementing guidance on September 23 (91 FR 60360). It lists eligible jurisdictions for the zero rate (including the European Union, India, Japan, South Korea, Switzerland and Liechtenstein, Taiwan, and the United Kingdom, among others), opens an urgent-need approval process by email to pharma232@bis.doc.gov with one product per application, and adds a zero-rate heading for pharmaceutical articles used solely for clinical trials, research and development, or other non-commercial purposes. It also corrected five items in Annex I and removed five tariff codes from Annex IV.
Two practical points. The urgent-need path is case by case, with Commerce consulting USTR and HHS, so it is a request, not an entitlement. And the clinical-trial heading matters to every sponsor importing investigational supply: confirm your customs broker is using it.
WHERE THE LEGAL RISK SITS
1. The rate depends on facts about the product and the company. The same active ingredient can face different rates depending on the finished product it goes into. A company’s rate depends on whether it has an onshoring plan or an MFN agreement. A legal department that treats “the tariff rate” as a single number will write contracts that cannot allocate the real cost.
2. Zero and reduced rates are conditional. Onshoring plans are approved, monitored and reported on by Commerce, and Commerce may require external audits of the reports. If the executive branch finds a company committed fraud or deliberately misled the government about onshoring commitments, the Secretary may reimpose tariffs prospectively and retroactively. Separately, the Secretary may increase rates for failure to meet company commitments, with notice in the Federal Register; that provision does not expressly address retroactivity. A tariff exposure that depends on continuing compliance with a government agreement is a covenant, and should be treated like one.
3. The exemption categories are narrow and fact-dependent. “Orphan-only” means every approved indication is orphan-designated. A product that adds a non-orphan indication loses the exemption, but the loss is delayed until the non-orphan indication is approved. Until then the product remains eligible. That makes the timing of a label expansion a tariff event: a sponsor planning a non-orphan supplemental application should model the rate that will apply from approval and plan supply and pricing before the approval date, not after it. Cell and gene therapy, ADC, and plasma categories depend on how Commerce and CBP classify the product.
4. Patent status drives tariff status. Because coverage requires a valid, unexpired US patent and Orange Book or Purple Book listing, patent expiry and delisting change a product’s tariff status. Product lifecycle events, including exclusivity loss and the entry of generics, therefore carry a customs consequence that supply and license agreements should anticipate.
5. Announcements are not law. The July 21 statement shows the risk of treating a presidential statement as a rate schedule. Contracts should key duty allocation to the proclamation, its annexes, and Federal Register notices, and should say so. A clause that refers to “announced tariffs” invites a dispute over what was announced.
6. The Supreme Court ruling does not decide this tariff. In Learning Resources, Inc. v. Trump (February 2026), the Supreme Court held that the International Emergency Economic Powers Act does not authorize the President to impose tariffs, and the emergency duties imposed under that statute fell. Proclamation 11020 rests on a different statute, Section 232 of the Trade Expansion Act of 1962, which carries its own procedures. The ruling therefore does not, by its terms, reach the pharmaceutical tariff. It does show that tariff authority is litigated, and that the legal basis for a duty can change after contracts are signed. Another point: the proclamation notes that pharmaceuticals are exempt from other special tariffs, and that this could change if the administration replaces the duties the Court struck down. Draft the change-in-law clause to cover a replacement or additional duty, and not only a change to Proclamation 11020.
BOX: SIX QUESTIONS FOR YOUR SUPPLY AND LICENSE AGREEMENTS
1. Who is importer of record, and who bears Section 232 duty? Silence defaults to the importer, which may not be the party that controls the sourcing decision.
2. Is there a change-in-law or tariff reopener? A fixed price with no reopener leaves the supplier or the buyer holding a 15 to 100 percent swing. Define the trigger by reference to the proclamation, annexes and Federal Register notices, not announcements, and cover replacement or added duties.
3. Does the contract say which rate the price assumes? Tie price to a defined duty rate or to the buyer’s status under an onshoring or MFN agreement.
4. What happens if a party loses its conditional status? If your supplier’s or partner’s reduced rate depends on a Commerce plan, a compliance failure is a pricing event for you. Require notice.
5. Who bears retroactive increases? Allocate in advance, including audit cooperation.
6. Can US-sourced API change the answer? Where the finished product can be made with US-sourced API, say who decides and who captures the saving. Also confirm clinical supply agreements use the research heading.
WHAT CHANGES IN DEAL DILIGENCE
Onshoring plans and MFN agreements are commitments made to the government, and the proclamation does not say what happens to them in a transaction. It is silent on whether an assignment or a change of control affects an MFN agreement. In an acquisition, that silence is the diligence item: ask what the target has signed, read the agreement itself for assignment and change-of-control terms, confirm with Commerce and HHS how they would treat the transaction, and make the answer a closing condition or a price adjustment where the tariff rate depends on it. Also ask what milestones remain and what the reporting and audit exposure is. For asset deals, ask whether the agreement attaches to the entity or the product. For a carve-out, revisit the transition services and supply terms, since the separated business may lose the parent’s tariff status.
WORKSTREAM 1 — IMMEDIATE: Classify Your Own Exposure
Map every imported product, active ingredient and starting material against Annex I and the zero-rate categories. Record for each: patent and Orange/Purple Book status, origin country, whether US-sourced API is used or available, which rate applies, and who is importer of record. Do not rely on a broker’s summary without checking.
BUSINESS IMPACT: The cost of a wrong classification is tariffs plus penalties plus a corrected price in contracts that assumed a different number.
WORKSTREAM 2 — NEAR-TERM: Amend Contracts That Run Past a Rate Change
Prioritize agreements with fixed pricing, long terms, or foreign contract manufacturers. Add duty allocation, a tariff reopener keyed to legal instruments, notice of loss of conditional status, and cooperation on audits.
BUSINESS IMPACT: A reopener negotiated now costs a conversation. A reopener negotiated after a rate change costs leverage.
WORKSTREAM 3 — STRATEGIC: Treat Government Commitments as Covenants
If your company has, or is negotiating, an onshoring plan or MFN agreement, give it the same governance as a material contract: an owner, a milestone calendar, board visibility, and a disclosure review. For generics, watch the Commerce report on generics due within a year of the proclamation.
BUSINESS IMPACT: A tariff rate that depends on keeping a promise to the government is only as stable as the compliance program behind the promise.
“A tariff rate that depends on keeping a promise to the government is a covenant. Treat it like one.”
For interested readers I have created a Section 232 Pharma Tarriff Contract Drafting Toolkit. It can be found at https://laroccaadvisory.gumroad.com/l/nvuwok.
ABOUT THE AUTHOR
John LaRocca is the founder of LaRocca Advisory Services and the author of The GC Playbook. He served as CLO at Aerie Pharmaceuticals (Aerie/Alcon, ~$930M), Y-mAbs Therapeutics (SERB, $412M), and Eagle Pharmaceuticals, with 37 years of legal experience and 26 years at the GC/CLO level in specialty pharma and biotech. The GC Playbook is published on Substack at laroccaj.substack.com.
© 2026 LaRocca Advisory Services | laroccaj.substack.com


